Bridge Biotherapeutics Presented Preclinical Study Results on BBT-877, an Autotaxin inhibitor at the IPF Summit 2018
BBT-877 demonstrated the best-in-class potential at the preclinical experiments in comparison with competing compounds US IND will be submitted by year end SEONGNAM, South Korea and SAN FRANCISCO, Aug. 23,…